Sleep Without Insomnia or The Use of Chronic Hypnotics
A legfontosabb adatok
- Ki végzi
- University of California, Los Angeles
- Hol
- Los Angeles (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 188 fő vett részt
- Kezdés
- 2018. dec. 11.
- Befejezés
- 2023. nov. 27.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Program A
- Program B
- A regiszteradat frissítve
- 2026. április 7.
Ki vehet részt
- Életkor
- 55 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Age >= 55 years
- Use of lorazepam, alprazolam, temazepam,and/or zolpidem for current or prior insomnia symptoms 2 or more nights per week for at least 3 months
- Current or prior insomnia symptoms
- Available to attend weekly in-person sessions over 9 weeks
Ki nem vehet részt
- High baseline risk of complicated withdrawal;benzodiazepine intoxication or current or past symptoms of complicated benzodiazepine/alcohol withdrawal (e.g.,seizure, delirium at baseline (prior to taper))
- Unable to keep study medications in secure location
- Medically/psychiatrically unstable (e.g., planned major surgery during the study period;psychosis, suicidal, active alcohol/substance abuse based on history and medical records)
- Seizure disorder
- Evidence of prescription fraud (e.g., multiple prescriptions for same drug filled at multiple pharmacies during overlapping time periods, diversion); Discontinuation of hypnotic not appropriate:; •Study-targeted hypnotic used to treat another clinical condition (e.g., panic disorder); Poor candidate for cognitive behavioral therapy for insomnia:
- Presence of bipolar disorder
- Cognitive impairment (e.g., Mini-Mental State Examination < 24)
- Sleep/wake difficulty is better explained by another sleep disorder such as restless legs syndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wake disorders
- High risk for complications in outpatient hypnotic discontinuation program:
- Supratherapeutic or high baseline hypnotic dose (> diazepam-equivalent of 8 mg/night)
- Polydrug use (e.g., chronic high dose opioids)
- Untreated sleep-disordered breathing (respiratory event index >= 15 and < 30 plus excessive daytime sleepiness, or REI >=30)
- Unstable housing situation
Helyszínek itt: Egyesült Államok
- University of California, Los AngelesLos Angeles, Egyesült Államok
- VA Greater Los AngelesLos Angeles, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Sleeping medications, called hypnotics, are often prescribed for insomnia and are associated with adverse health outcomes in older adults. Response rates to hypnotic discontinuation programs are often inadequate, and many patients eventually resume use of hypnotics, suggesting that other mechanisms need to be targeted to achieve and sustain high rates of non-use. Current programs focus on the tapering of hypnotics and/or the treatment of insomnia symptoms. These programs employ strategies such as supervised gradual taper, cognitive behavioral therapy targeting hypnotic withdrawal, and/or cognitive behavioral therapy for insomnia. Evidence suggests that another mechanism involving "placebo" effects may be a viable target for achieving and sustaining higher discontinuation rates. Cognitive expectancies play a key role in producing placebo effects, which are characterized as real improvements in sleep arising from psychosocial aspects of treatment rather than drug effects alone. In this study, investigators are comparing two programs for discontinuing hypnotic medications-a program that addresses placebo effects associated with hypnotic use and a program that does not address these effects.
A vizsgálat 2 csoportja
- Program AA vizsgált kezelés
cognitive behavioral therapy type A plus medications in packaging type A
- Program BMár használt kezelés, összehasonlításként
cognitive behavioral therapy type B plus medications in packaging type B
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Novel Mechanism for Helping Older Adults Discontinue Use of Sleeping Pills
- Publikációk
- Sleep aid usage following benzodiazepine receptor agonist tapering and cognitive behavioral therapy for insomnia in middle-aged and older adults.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026
- Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.JAMA internal medicine, 2024
- A regiszteradat frissítve
- 2026. április 7.